Oncimmune’s CEO, Martin Gouldstone spoke to Thomas Warner from Proactive London about the positive results the new business strategy has had so far and about what he describes as essentially the relaunch of Oncimmune as a whole.
Since he was appointed CEO earlier this year, there have been significant changes made to the company’s strategy. The primary focus has been on maximising the commercial and scientific value of the company’s ImmunoInsights platform and bringing the centre back to the company’s headquarters in Dortmund, Germany.
According to the new strategy, the aim is to expand the platform’s capabilities in drug discovery and development and reach different customer verticals, extending from big pharma to smaller biopharma and CRO partnerships.
Watch the whole interview below: